Morphine- and buprenorphine-induced analgesia and antihyperalgesia in a human inflammatory pain model: a double-blind, randomized, placebo-controlled, five-arm crossover study

Pernille Ravn1
Erik L Secher2
Ulrik Skram3
Trine Therkildsen1
Lona L Christrup1
Mads U Werner4

1Department of Drug Design and Pharmacology, University of Copenhagen, 2Department of Anesthesiology, Juliane Marie Center, Rigshospitalet, Copenhagen University Hospitals, 3Department of Intensive Care, Gentofte Hospital, Copenhagen University Hospitals, 4Multidisciplinary Pain Center, Neuroscience Center, Rigshospitalet, Copenhagen University Hospitals, Copenhagen, Denmark

Correspondence: Pernille Ravn
Department of Drug Design and Pharmacology, University of Copenhagen, Universitetsparken 2, 2100 Copenhagen, Denmark
Tel +45 2345 6283
Fax +45 3533 6050
Email ravn@farma.ku.dk

Purpose: Opioid therapy is associated with the development of tolerance and paradoxically increased sensitivity to pain. It has been suggested that buprenorphine is associated with a higher antihyperalgesia/analgesia ratio than µ-opioid receptor agonists. The primary outcome of this study was therefore to investigate relative differences in antihyperalgesia and analgesia effects between morphine and buprenorphine in an inflammatory pain model in volunteers. The secondary outcome was to examine the relationship between pain sensitivity and opioid-induced effects on analgesia, antihyperalgesia, and descending pain modulation.

Subjects and methods: Twenty-eight healthy subjects were included. The study was a double-blind, randomized, placebo-controlled, five-arm crossover study with a multimodal (electrical, mechanical, and thermal stimuli) testing technique. After baseline assessments, intravenous infusions of morphine (10/20 mg), buprenorphine (0.3/0.6 mg), or placebo (normal saline) were administered over a 210-minute period, during which a cold pressor test, heat injury (47 °C, 7 minutes, 12.5 cm²), and the first postburn assessment were done. After completion of the drug infusions, two additional postburn assessments were done. The subjects were monitored during each 8-hour session by an anesthesiologist.

Results: For nearly all tested variables, significant dose-dependent analgesic effects were demonstrated. The median antihyperalgesia/analgesia ratio (secondary hyperalgesia/heat injury relative to placebo) for low-dose morphine was 0.01 (interquartile range: −6.2; 9.9), 0.00 (−2.4; 2.1) for high-dose morphine, 0.03 (−1.8; 2.1) for low-dose buprenorphine, and 0.00 (−3.2; 1.1) for high-dose buprenorphine (P > 0.466). There were no significant differences in opioid responses between high and low pain-sensitive subjects (P > 0.286). High-dose buprenorphine, compared to placebo, was associated with a significantly enhanced action of the descending inhibitory pain control system (P = 0.004).

Conclusion: The present study, using multimodal testing technique, could not demonstrate any significant differences between morphine and buprenorphine in the profiles of antihyperalgesia and analgesia. Only high-dose buprenorphine was associated with a significant effect on the descending inhibitory pain control system.

Keywords: analgesia, antihyperalgesia, experimental pain, opioid, pain sensitivity, randomized trial

Introduction
Opioids are generally considered cornerstones in management of high intensity acute and chronic pain. The opioid-mediated pain reduction is mainly caused by activation of opioid-receptors in the central nervous system, at spinal and supraspinal levels.
Although peripherally mediated suppression of sensitized nociceptors by opioids has been reported, the general absence of antihyperalgesic effects in clinical studies suggests that opioids generally have only a minor effect in preventing central sensitization of the pain pathways. Furthermore, opioid therapy is associated with a development of tolerance and a paradoxically increased sensitivity to pain, ie, opioid-induced hyperalgesia. This is obviously of clinical concern since opioid therapy per se may aggravate pain and thus endanger adequate pain control. Different mechanisms have been proposed for opioid-induced hyperalgesia and opioid-induced analgesia. In a human experimental electrical pain model, buprenorphine – a partial μ-opioid receptor (MOR) agonist and κ-opioid receptor (KOR) antagonist – seems to be associated with a higher antihyperalgesia/analgesia ratio than conventional MOR agonists morphine and fentanyl. If this also holds true for an inflammatory stimulus associated with primary and secondary hyperalgesia (2HA), the observations may implicate potential opioid receptor-specific effects on analgesia and antihyperalgesia in a clinical setting.

Furthermore, large variations in pain sensitivity and analgesic response profiles have been demonstrated in experimental and clinical research. A number of studies have shown that sensitivity to suprathreshold heat and pressure pain consistently predicts postoperative pain outcomes and susceptibility to chronic pain disorders. The descending conditioned pain modulation (CPM) system may be an important factor regulating pain sensitivity and the propensity for development of chronic pain. Recent human experimental data suggest that both fentanyl and buprenorphine increase the effect of descending pain inhibition using CPM. A better insight into the interaction between pain sensitivity and opioid response profile may lead to an increased understanding of clinical pain and its management.

The primary outcome of the study was to investigate relative differences in effects on antihyperalgesia and analgesia between morphine and buprenorphine in a validated, clinically relevant, inflammatory injury model. The secondary outcome was to examine the relationship between pain sensitivity and opioid-induced effects on analgesia, antihyperalgesia, and descending pain modulation.

Subjects and methods

Subjects

The protocol was approved by the Regional Ethics Committee (H-2-2010-115), Danish Medicines Agency, Danish Data Protection Agency, and ClinicalTrials.gov (NCT01296334). Healthy subjects were recruited from a prior study; the volunteers with the highest and lowest pain responses (based on their visual analog scale [VAS] scores during the heat injury) were asked to participate in the present study. Inclusion criterion was 20–40 years of age. Exclusion criteria were insufficient proficiency in Danish, participation in other clinical trials in the last 4 weeks prior to the present study, skin lesions on the lower leg, intake of any medication 48 hours prior to the investigation, intake of analgesics 7 days prior to the investigation (except paracetamol), allergy to morphine, buprenorphine, hydrocortisone, ondansetron, or dehydrobenzperidol, current or former drug abuse, smoking, body mass index > 28, and, in females, pregnancy, planning of pregnancy, or no use of contraception. Following verbal and written information, all subjects provided written informed consent before inclusion. All subjects had a routine medical examination by a physician prior to inclusion. Subjects received a compensation of €675, equivalent to USD890, for the five 8-hour study sessions.

Study design

The study was a double-blind, randomized, placebo-controlled, five-arm crossover study. Each study day was identical with only the study drugs differing between the five sessions (Figure 1).

Study drugs

Buprenorphine (0.3 mg/mL; Temgesic®; Reckitt Benckiser plc, Slough, United Kingdom) and morphine (20 mg/mL; morfin SAD) was mixed with and administered in 480 mL of 0.9% sodium chloride. Buprenorphine (0.3 and 0.6 mg), morphine (10 mg and 20 mg), and placebo (0.9% sodium chloride) were administered as intravenous infusions over a 210-minute period. The target-controlled infusion regimens were chosen in order to obtain steady-state concentrations (until 1 hour postburn), and simulations were performed with pharmacokinetic calculation software (Berkeley Madonna version 8.3.18; University of California – Berkeley, Berkeley, CA), using data from Yassen et al and Mazoit et al. The dose was administered according to the following infusion regimen: 0–15 minutes, one-quarter of the dose was infused; 15–210 minutes, the remaining three-quarters of the dose was infused. The doses were chosen as an attempt to minimize potential adverse events, especially nausea and vomiting, but at the same time reach a significant difference between the high and low doses. Furthermore, to reduce the risk of adverse events, antiemetics (25 mg hydrocortisone succinate [Solu-Cortef®; Pfizer, Inc, New York, NY] and 2 mg
ondansetron (Zofran®; GlaxoSmithKline plc, London, United Kingdom) were administered prior to baseline assessments. Isotonic glucose (1 L) was administered (as an intravenous infusion during the 6-hour session) to attenuate the discomfort of fasting as the subjects were instructed not to eat and drink 8 hours and 2 hours, respectively, prior to study drug administration.

The randomization, blinding, and packaging of the drugs were performed by Herning Hospital Pharmacy (Herning, Denmark) using the second generator at randomization.com. The second generator creates random permutations of treatments for situations where subjects receive all of the treatments in random order. The packaging was identical for all five study drugs and the drug infusions were prepared 1–12 hours before use by pharmaceutical trained staff not involved in other parts of the study.

### Monitoring and surveillance

All volunteers had a routine medical examination including an electrocardiogram taken before the first drug infusion. Noninvasive arterial blood pressure, heart rate, respiratory rate, and oxygen saturation were monitored and registered during the entire sessions. A registered nurse in anesthesia and an anesthesiologist were present during the full-length of the sessions, and the latter was responsible for the discharge of the subjects at the end of the study.

### Psychological tests

At the first study session the volunteers completed the Hospital and Anxiety Depression Scale (HADS), Pain Catastrophizing Scale (PCS), and Psychological Vulnerability Scale. HADS is a 14-item questionnaire used to evaluate the subjects' level of anxiety and depression. The subjects can rate between zero and 21, with a score of eleven as the cutoff point for anxiety or depression.

PCS is a 14-item questionnaire used to assess the subjects' rumination, magnification, and helplessness. The subjects can rate between zero and 52, with a total PCS score of 30 representing a clinically relevant level of catastrophizing. The Psychological Vulnerability Scale is a six-item questionnaire used to determine the subjects' psychological vulnerability. The subjects can rate between zero and twelve, with a score of three as the cutoff point.

### Psychomotor performance

The finger tapping test (FTT) was used at the beginning and at the end of each session to test the subjects' psychomotor performance. FTT is a simple reaction time measurement, where the subjects press a spring lever with their dominant index finger as many times as possible in 10 seconds. This is repeated five times and the average scores from the initial (predrug) and final (postdrug) tests from each session were compared as a control of the normalization of the subjects' psychomotor performance.
Perception of drug effect/drug liking
At the end of each session, the subjects rated the drug effect and drug liking of the given treatment. The subjective drug effect was evaluated on a scale from 0 to 5 (0 = no effect, 5 = maximum effect) and the liking was evaluated on a scale from 0 to 10 (0 = feeling extreme discomfort, 5 = neither discomfort nor comfort, 10 = feeling extreme comfort). Subjects with a drug effect score of at least 4 and a drug liking score of at least 8 were excluded from continuing on in the trial. Moreover, a drug liking score of at least 9, regardless of the drug effect score, would exclude a subject from the remaining part of the study.

The drug effect scores were reduced by five in order to interrelate the two scales so that zero equaled no effect and no like/dislike (negative 5 = extreme discomfort, 5 = extreme comfort).

Retrospective identification of placebo day
At the end of the fifth, and final, session, the subjects were asked to identify the study day on which they believed they had received the placebo.

Psychophysiological pain tests
Environment and testing paradigm
All tests were performed in a well-lit room (21°C–24°C, 24%–45% relative humidity) with the subjects comfortably relaxed in the supine position. The subjects were blinded to the test results during the study.

Assessments were made on five study sessions, each of 8 hours duration and separated by a minimum of 2 weeks. Two investigators (PR, TT) made the assessments. The study algorithm is illustrated in Figure 1.

Testing areas
The testing area for thermal thresholds and 2HA was the upper medial part of the nondominant lower leg. The subjects were instructed to use a hair trimmer in the area 2 days before the study days in order to avoid interference from the tactile stimulation of hairs. The three other testing areas were the nondominant thumb and index finger for electrical thresholds, the nondominant index finger for pressure thresholds, and the dominant hand for CPM and cold pressor test (CPT).

Electrical stimulation
Transcutaneous electrical stimuli were applied by a computerized, constant current stimulator (PainMatcher®; Cefar Medical AB, Lund, Sweden). The stimulator delivers square wave impulses with a frequency of 10 Hz and an amplitude of 15 mA. The stimulation intensity is automatically modulated by increasing the pulse width (in 4 microsecond increments) from 4 microseconds to a maximum of 396 microseconds. The subject pinches the two opposing rubber electrodes between the nondominant thumb and index finger. By holding a steady grip on the electrodes, an incremental increase in the electrical energy is delivered. When releasing the pinch grip a value between one and 100, reflecting the energy delivered, is registered. The electrical detection threshold (EDT), electrical pain threshold (EPT), and electrical pain tolerance (EPTo) were assessed.

Mechanical stimulation
Electronic pinprick algometry
The pinprick pain threshold was measured by an electronic pinprick algometer (Electronic von Frey; Somedic AB, Horby, Sweden). The contact diameter of the probe was 0.2 mm (area 0.031 mm²). At each start-up, the algometer was calibrated against gravity (0 g) and a calibrated weight (20 g). In order to not exceed a range of skin pressures that could inflict tissue damage, the electronic pinprick algometer has a cutoff force value of 4.41 N. The subjects were told to indicate the pain threshold on an electronic visual analog scale (VAS) without indicator markings (horizontal 10 cm line anchored by 0 = no pain and 10 = maximum pain imaginable). The pinprick pain threshold corresponded to a minimum detectable movement of the ruler (electronic VAS = 0.02).

Monofilaments
The area of 2HA in normal skin surrounding the area of the heat injury was determined with a nylon filament (nominal value mean ± standard deviation: #18 [0.89 ± 0.05 N]; Stoelting Co, Wood Dale, IL). The border was determined by stimulating in eight symmetric lines, each separated by an angle of 45 degrees converging towards the center of the heat injury. The subjects, who had their eyes closed during the assessments, reported the occurrence of a definite uncomfortable change in sensation to a burning or stinging sensation. The corners of the octagon were marked on the skin and transferred to a transparent sheath. The 2HA areas were calculated (total area minus area of the thermode) using a computer-based vector algorithm (Canvas 12.0; ACD Systems International, Victoria, Canada).
Thermal stimulation
Warmth detection threshold (WDT), cool detection threshold (CDT), heat pain threshold (HPT)
Thermal stimuli were delivered through a computerized system (MSA Thermostest®; Somedic AB) using a Peltier thermode with a contact area of 5.0 × 2.5 cm². Thermal neutrality was defined as 32°C, and cutoff values for heat and cold stimuli were 50°C and 10°C, respectively. The ramp rates were ±2°C/second. The subjects were told to activate a button immediately at sensation of a change in temperature (WDT, CDT) and when the heat was perceived as pain (HPT). After activation of the button, the thermode returned to 32°C. At each study session, each test was performed in triplicate with random intervals of 2–6 seconds between the three runs, and the median value was used.

Heat injury
A first-degree heat injury was induced by the thermode (47°C, 420 seconds) applied to the lower nondominant leg. The injury is associated with development of erythema and tenderness. The subject rated the pain on a VAS (0 = no pain, 10 = maximum pain imaginable) immediately when 47°C had been reached, after 30 seconds, and thereafter every 60 seconds. The cumulated pain intensity during the heat injury (PHI) was calculated as follows:

\[ \text{PHI} = (\text{VAS}_{60s} + \text{VAS}_{120s}) \times 0.5 + \text{VAS}_{120s} \times 0.5 + \text{VAS}_{120s} \times 0.5 + \text{VAS}_{420s} \]  

(1)

Antihyperalgesia/analgesia ratio
The ratio of antihyperalgesia/analgesia (Δ2HA/ΔPHI and Δ2HA/ΔEPTo) was calculated using the mean 1–3 hour postburn values of the 2HA areas divided by the placebo-corrected PHI scores or the mean values of the placebo-corrected EPTo, respectively, with equations two and three leading to equation four:

\[ \Delta 2 \text{HA} (%) = 100 \times \frac{2 \text{HA}_{\text{mean}}^{\text{placebo}} - 2 \text{HA}_{\text{mean}}^{\text{opioid}}}{2 \text{HA}_{\text{mean}}^{\text{placebo}}} \]  

(2)

\[ \Delta \text{PHI} (%) = 100 \times \frac{\text{PHI}_{\text{mean}}^{\text{placebo}} - \text{PHI}_{\text{mean}}^{\text{opioid}}}{\text{PHI}_{\text{mean}}^{\text{placebo}}} \]  

(3)

\[ \frac{\Delta 2 \text{HA}}{\Delta \text{PHI}} = \frac{\text{PHI}_{\text{mean}}^{\text{placebo}}}{2 \text{HA}_{\text{mean}}^{\text{placebo}}} \times \frac{2 \text{HA}_{\text{mean}}^{\text{placebo}} - 2 \text{HA}_{\text{mean}}^{\text{opioid}}}{\text{PHI}_{\text{mean}}^{\text{placebo}} - \text{PHI}_{\text{mean}}^{\text{opioid}}} \]  

(4)

CPT and pressure algometry
A recirculating 0.9% saline-based chiller (model 11371P; VWR International, Radnor, PA) with a bath volume of 13 L was used for the CPT. The temperature was maintained at 0.3°C–0.5°C. An electronic algometer with a 1 cm² neoprene-coated tip (Somedic AB; rate: 30–40 mN/second) was applied on the dorsum of the distal phalanx of the dominant index finger (deep sensitivity pain). The subject was told to activate a button terminating the stimulus when the maximum tolerable pressure level was reached (PTo1). The subject then submerged the nondominant hand in the bath maintaining the water level at 1–2 cm above the wrist, spreading the fingers, and allowing water freely to circulate around the hand. The time to pain registration (ie, CPT pain threshold [CPP]) and time to pain tolerance (ie, CPT pain tolerance [CPTo]) were registered. Immediately after withdrawal of the hand from the bath, a second pressure algometry test at the dominant index finger was made (PTo2). The difference in pressure pain thresholds was calculated as \( \Delta \text{PTo} = \text{PTo2} - \text{PTo1} \).

CPM efficiency
The CPM efficiency test has been used in clinical studies to predict the development of chronic postoperative pain. In the CPM efficiency paradigm, repeated short heat stimuli (47°C, 4 seconds; Figure 3) were applied to the nondominant lower leg (nonglabrous skin) in relation to the submersion of the nondominant hand in the CPT water bath (0.3°C–0.5°C, 30 seconds). During the heat stimuli, the subjects rated their maximal pain (CPM1 – CPM4; Figure 3) on the VAS. The subjects were instructed only to evaluate the pain from the heat stimulation. CPM efficiency was calculated as:

\[ \Delta \text{CPM}(\%) = 100 \times \left(1 - \frac{\text{CPM2} + \text{CPM3} + \text{CPM4}}{3 \times \text{CPM1}}\right) \]  

(5)

Pain sensitivity
Definition of pain sensitivity
Pain sensitivity has been defined as the proneness to react to standardized experimental or pathological stimuli. Pain ratings of seemingly identical noxious stimuli may range from “no pain” to “excruciating pain”. The volunteers in the present study were categorized as high or low pain-sensitive subjects based on their PHI from a preceding study (n = 100). The tertiles with the highest and lowest pain scores were recruited, resulting in 64 intention-to-treat subjects.
Statistical analyses

The power analysis was based on the estimates that the antihyperalgesia/analgesia \( (\Delta 2HA/\Delta PHI) \) ratio was 2.6,\(^6\) the intraindividual standard deviation was 1.5, and the minimal detectable difference was 1.8. On the assumptions that the power was set to 0.9 and the significance level to 0.01, a minimum of 25 subjects was needed. The power analysis was based on the lower buprenorphine dose (0.3 mg).

For all the postburn assessments (1–3 hours postburn), the analyses used mean values and the data were baseline (preburn) corrected. The data were tested for pain sensitivity-dependent differences on placebo as well as the opioid treatments corrected for placebo. In the case of floor or ceiling effect, nonparametric analysis was used with the maximum obtainable value plus one or the minimum obtainable value changed from 0 to 0.01.

All data were tested for normal distribution and parametric analyses were performed where possible. In nonnormal distributions, transformations were tried. In nonsuccessful transformations, nonparametric analyses were performed. Analyses of the differences between the treatments and pain sensitivity were done by repeated measures one-way analysis of variance (ANOVA). In cases of significance \( (P < 0.05) \), paired \( t \)-tests or Wilcoxon signed-rank tests (based on the distribution) were performed. The psychological variables were analyzed with Fischer’s exact test. All statistics were performed with PASW version 18.0 (IBM Corporation, Armonk, NY).

There were five treatment groups for each outcome, resulting in ten pairwise comparisons. In order to reduce the likelihood of a type I error caused by multiple comparisons, the significance level was set at \( P < 0.005 \) for all analyses, based on a standard Bonferroni correction. Continuous data are presented as mean ± standard error of the mean unless otherwise stated.

Results

Subjects

The intention-to-treat and per-protocol groups were 33/33 (males/females) and 13/14, respectively (Figure 2).

One subject only completed four treatments due to exclusion for the remaining part of study (low-dose
Psychological variables

None of the subjects had HADS subscores indicating depression symptoms. One male subject had a HADS subscore demonstrating anxiety (score = 14) and three subjects (one male, two females) had Psychological Vulnerability Scale scores indicating psychological vulnerability. Eight subjects (five males and three females) had Pain Catastrophizing Scale (PCS) scores indicating catastrophizing thoughts. The PCS scores for males and females were 6.0 and 5.3 for rumination, 2.1 and 1.8 for magnification and 4.4 and 3.7 or helplessness, respectively.

No significant correlations between any of the psychometric variables and gender (P > 0.343) or sensitivity (P > 0.067) were observed.

Psychomotor performance

The subjects had a higher score on the FTT at the end of the sessions (postdrug) compared to the test performed at the beginning of the sessions (predrug), with an overall increase of 4.3 taps. No significant differences were seen between the five sessions on the predrug FTT (P > 0.063) or the postdrug FTT (P > 0.359).

Drug effect/drug liking

The subjective rating of the drug effect during the opioid treatments differed significantly from placebo (P < 0.0001; Figure 4). Increased drug effect was observed for both doses of buprenorphine and high-dose morphine compared to low-dose morphine and for high-dose buprenorphine compared to high-dose morphine (P < 0.0001). The rating for drug liking demonstrated a lower score for high-dose buprenorphine compared to low-dose morphine (P = 0.004). None of the other opioid comparisons differed (P > 0.010), nor did any of the opioids compared to placebo (P > 0.016).

Retrospective identification of the placebo day

Twenty-three (85%) subjects identified the correct study session as the placebo treatment. Four subjects (15%) identified low-dose morphine as the placebo treatment.

Psychophysiological pain tests

Several tests contained floor or ceiling values and several subjects reached these cutoff values (Table 2).

Baseline comparisons

All the tests performed before drug infusion (baseline assessments; Figure 1) were analyzed for differences between

---

Table 1 Anthropometric data

<table>
<thead>
<tr>
<th>Gender</th>
<th>Age (years)</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>BMI (kg/m²)</th>
<th>BSA (m²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Females (n = 13)</td>
<td>23.2 (2.0)</td>
<td>168.3 (6.2)</td>
<td>64.7 (7.4)</td>
<td>22.9 (2.6)</td>
<td>1.74 (0.12)</td>
</tr>
<tr>
<td>Males (n = 15)</td>
<td>26.7 (4.3)</td>
<td>184.4 (7.5)</td>
<td>81.0 (9.4)</td>
<td>23.8 (2.2)</td>
<td>2.03 (0.15)</td>
</tr>
<tr>
<td>Females and males</td>
<td>25.1 (3.8)</td>
<td>176.9 (10.6)</td>
<td>73.4 (11.8)</td>
<td>23.4 (2.4)</td>
<td>1.90 (0.20)</td>
</tr>
</tbody>
</table>

Notes: Age (years), height (cm), weight (kg), BMI (kg/m²) and BSA (m²) for females, males and both genders combined (mean [SD]).

Abbreviations: BMI, Body Mass Index; BSA, Body Surface Area; SD, standard deviation.
the five study sessions and for potential pain sensitivity differences (low versus high pain-sensitive subjects). None of the baseline assessments before drug infusion differed significantly between the sessions (Table 3).

In baseline assessments of EPTo, significant differences in pain sensitivity were found for the sessions when high-dose morphine, high-dose buprenorphine, and placebo were administered ($P < 0.005$; Table 3).

**Comparisons across treatments**

**Electrical stimulation**

The repeated measures ANOVA showed significant differences between the treatments for all three electrical tests:

**Table 2 Tests affected by floor or ceiling values**

<table>
<thead>
<tr>
<th>Test</th>
<th>Cut-off</th>
<th>Placebo</th>
<th>Morphine Low</th>
<th>Morphine High</th>
<th>Buprenorphine Low</th>
<th>Buprenorphine High</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceiling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EPTo, preburn</td>
<td>100</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>EPTo, PB1</td>
<td>Units</td>
<td>1</td>
<td>4</td>
<td>7</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>EPTo, PB2</td>
<td></td>
<td>1</td>
<td>3</td>
<td>6</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>EPTo, PB3</td>
<td></td>
<td>1</td>
<td>3</td>
<td>6</td>
<td>5</td>
<td>8</td>
</tr>
<tr>
<td>HPT, preburn</td>
<td>50°C</td>
<td>4</td>
<td>4</td>
<td>5</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>HPT, PB1</td>
<td></td>
<td>5</td>
<td>5</td>
<td>5</td>
<td>8</td>
<td>11</td>
</tr>
<tr>
<td>HPT, PB2</td>
<td></td>
<td>5</td>
<td>10</td>
<td>9</td>
<td>12</td>
<td>17</td>
</tr>
<tr>
<td>HPT, PB3</td>
<td></td>
<td>6</td>
<td>10</td>
<td>8</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>CPP</td>
<td>180 sec</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>CPTo</td>
<td></td>
<td>9</td>
<td>12</td>
<td>13</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td>PTo1</td>
<td>1,600 g</td>
<td>1</td>
<td>5</td>
<td>6</td>
<td>2</td>
<td>4</td>
</tr>
<tr>
<td>PTo2</td>
<td></td>
<td>0</td>
<td>2</td>
<td>4</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Floor</td>
<td></td>
<td></td>
<td>6</td>
<td>5</td>
<td>6</td>
<td>5</td>
</tr>
<tr>
<td>2HA, PB 1</td>
<td>0 cm$^2$</td>
<td>6</td>
<td>5</td>
<td>6</td>
<td>5</td>
<td>6</td>
</tr>
<tr>
<td>2HA, PB 2</td>
<td></td>
<td>6</td>
<td>5</td>
<td>5</td>
<td>7</td>
<td>6</td>
</tr>
<tr>
<td>2HA, PB 3</td>
<td></td>
<td>6</td>
<td>6</td>
<td>5</td>
<td>10</td>
<td>7</td>
</tr>
</tbody>
</table>

**Notes:** Number of subjects for each assessment variable reaching floor or ceiling values divided on placebo, low- and high-dose morphine and low- and high-dose buprenorphine ($n = 28$ in all groups, except low-dose morphine, $n = 27$).

**Abbreviations:** EPTo, electrical pain threshold; HPT, heat pain threshold; CPP, cold pressor test pain threshold; CPTo, cold pressor test pain tolerance; PTo1, pressure pain tolerance (before CPT); PTo2, pressure pain tolerance (after CPT); 2HA, secondary hyperalgesia area; PB1, 1 hour postburn; PB2, 2 hours postburn; PB3, 3 hours postburn.

EDT, EPT, and EPTo ($P = 0.001, P = 0.001$, and $P = 0.0001$, respectively).

No significant differences were seen in EDT when comparing opioids to placebo ($P > 0.027$) or when comparing opioids reciprocally ($P > 0.016$).

Analgesic effects in EPT and EPTo assessments were seen with both doses of buprenorphine and high-dose morphine when compared to placebo ($P < 0.0001$ and $P < 0.0001$, respectively), but not when comparing low-dose morphine with placebo ($P = 0.454$ and $P = 0.011$, respectively; Figure 5). Comparing the opioid treatments, a significant lower analgesic effect was seen in EPT for low-dose morphine compared to the two doses of buprenorphine and high-dose morphine ($P < 0.005$). EPTo was also significantly lower for low-dose morphine compared to the two doses of buprenorphine ($P < 0.003$).

**Thermal stimulation**

Differences between the treatments were seen in CDT and HPT ($P = 0.0001$), but not in WDT ($P = 0.236$).

**CDT**

Significantly decreased CDTs (numerically increased thresholds) were observed for both doses of buprenorphine and high-dose morphine compared to placebo ($P < 0.0001$), while significantly increased CDTs (numerically decreased thresholds) were seen for low-dose morphine compared to placebo ($P = 0.0001$) and low-dose buprenorphine compared to the two doses of buprenorphine ($P < 0.002$; Figure 6).

**HPT**

A significantly increased analgesic effect was found for high-dose buprenorphine compared to placebo ($P = 0.001$). High-dose buprenorphine also showed a significantly increased analgesic effect when compared to both doses of morphine ($P < 0.001$; Figure 6).

**Heat injury**

The repeated measures ANOVA revealed significant differences between the treatments in relation to PHI ($P = 0.0001$). A significant analgesic effect during the heat injury was demonstrated for both doses of buprenorphine and high-dose morphine compared to placebo ($P < 0.003$; Figure 7), but not for low-dose morphine compared to placebo ($P = 0.022$). The analgesic effect of high-dose buprenorphine was also significantly larger compared to the analgesic effect of low-dose morphine ($P = 0.002$).
pressure stimulation and CPT

No significant differences were found between the first and second pressure stimulation test in any of the treatment groups (P = 0.708), but a trend in treatment differences were seen in PTo1 and PTo2 (P = 0.008 and P = 0.006, respectively). The repeated measures ANOVA also showed significant differences in CPP and CPTo (P = 0.015 and P = 0.0001).

Pressure pain tolerances (PTo1, PTo2) were significantly lower in the placebo group compared to high-dose buprenorphine and high-dose morphine (P < 0.005), and the difference in pressure pain thresholds was significantly lower for placebo compared to high-dose buprenorphine (P = 0.003; Figure 8).

A significant increase in CPPs was seen with both doses of buprenorphine and high-dose morphine compared to placebo (P < 0.004; Figure 8). All opioid treatments significantly increased CPTo compared to placebo (P < 0.001; Figure 9), but none of the opioid treatments differed significantly (P > 0.009).

CPM efficiency

The repeated measures ANOVA revealed significant differences in CPM efficiency (P < 0.001).

High-dose buprenorphine showed a significant analgesic effect compared to placebo (P = 0.004; Figure 10), which was not seen when comparing the other three opioids to placebo (P > 0.012). No significant differences were found when comparing the opioid treatments reciprocally (P > 0.009).

Table 3 Baseline comparisons

<table>
<thead>
<tr>
<th>Differences between</th>
<th>EDT</th>
<th>EPT</th>
<th>EPTo</th>
<th>WDT</th>
<th>CDT</th>
<th>HPT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sessions</td>
<td>&gt;0.363</td>
<td>&gt;0.187</td>
<td>&gt;0.065</td>
<td>&gt;0.057</td>
<td>&gt;0.132</td>
<td>&gt;0.041</td>
</tr>
<tr>
<td>High and low pain sensitive subjects</td>
<td>&gt;0.009</td>
<td>&gt;0.310</td>
<td>&gt;0.005</td>
<td>&gt;0.114</td>
<td>&gt;0.333</td>
<td>&gt;0.248</td>
</tr>
</tbody>
</table>

Notes: Baseline comparison of the five baseline measurements (between sessions) and tests for pain sensitivity differences (between high- and low pain sensitive subjects). Lowest P-values from the 10 comparisons are reported.

Abbreviations: EDT, electrical detection threshold; EPT, electrical pain threshold; EPTo, electrical pain tolerance; WDT, warmth detection threshold; CDT, cold detection threshold; HPT, heat pain threshold.

Figure 5 Electrical pain threshold and electrical pain tolerance.

Notes: Electrical pain threshold and electrical pain tolerance for baseline, postburn 1–3 assessments and mean postburn assessments. The asterisks on baseline values indicates differences between baseline and its respective mean postburn value, while asterisks on mean postburn values indicate differences between the five sessions mean postburn assessments.

Abbreviations: EPT, Electrical pain threshold; EPTo, electrical pain tolerance; Mean PB, mean of PB1, PB2 and PB3; PB1, 1 hour postburn; PB2, 2 hours postburn; PB3, 3 hours postburn.

Figure 6 Cool detection threshold and heat pain threshold.

Notes: Cool Detection Threshold (CDT) and Heat Pain Threshold (HPT) for baseline, postburn 1–3 (PB1-3) and mean postburn (mean PB) assessments. The asterisks on baseline values indicate differences between baseline and its respective mean postburn value while asterisks on mean postburn values indicate differences between the five sessions mean postburn assessments.

Abbreviations: CDT, cool detection threshold; HPT, heat pain threshold; Mean PB, mean of PB1, PB2 and PB3; PB1, 1 hour postburn; PB2, 2 hours postburn; PB3, 3 hours postburn.
2HA

Repeated measures ANOVA did not demonstrate any significant differences in the areas of 2HA ($P = 0.773$; Figure 11).

**Antihyperalgesic/analgesic effect**

No significant differences were seen when comparing the opioids in regard to $\Delta$2HA/$\Delta$PHI ($P > 0.466$). In regard to $\Delta$2HA/$\Delta$PTo, significant differences were only seen in low-dose morphine compared to the other active groups ($P < 0.001$). The antihyperalgesic/analgesic effect values relative to placebo and the ratios are presented in Figure 12.

**Pain sensitivity differences**

Only the heat injury at the placebo session showed significant pain sensitivity differences ($P = 0.001$).

**Adverse events**

Nausea, vomiting, itching, sedation, and arterial desaturation were the most frequent adverse events (Table 4). A significant increased number of adverse events were seen for both doses of buprenorphine and for high-dose morphine compared to placebo ($P < 0.0001$), while no significant difference between low-dose morphine and placebo was observed ($P = 0.027$). An increased number of adverse events were reported during treatment with high-dose buprenorphine compared with the other treatments ($P < 0.003$). There was no significant difference in the total number of adverse events reported in low-dose buprenorphine compared to high-dose morphine ($P = 0.700$), both of which had an increased rate of adverse events compared to low-dose morphine ($P < 0.001$). No serious or unexpected adverse events occurred. No significant differences in the number of adverse events between high and low pain-sensitive subjects were seen ($P = 0.156$).

**Discussion**

The present study could not demonstrate any clear differences between morphine and buprenorphine in the antihyperalgesia/analgesia profiles, using an inflammatory pain model with multimodal testing technique in healthy subjects. Furthermore, no differences between high and low pain-sensitive subjects in morphine- and buprenorphine-induced antihyperalgesia and analgesia were observed. High-dose buprenorphine, compared to placebo, was associated with a significant increased action of the descending inhibitory pain control system.

**Implications**

The main finding of the present study is clearly at odds with the seminal study by Koppert et al, which used...
an electrical model with intradermal stimulation and a placebo-controlled administration of buprenorphine (0.15 mg intravenously/5 minutes). Their study demonstrated that buprenorphine reduced the hyperalgesic areas by 66% and the pain ratings by 26%, leading to an antihyperalgesia/analgesia ratio of median 2.6 (interquartile range: 0.8; 3.8). The authors concluded, on the basis of recalculation of historical opioid data, that in contrast to pure MOR agonists (eg, fentanyl and alfentanil) with antihyperalgesia/analgesia ratios of 0.6 (–0.3; 2.2) and 0.3 (–0.3; 0.5), respectively, it seemed that buprenorphine exerted a more prominent antihyperalgesic than analgesic effect.

A number of differences between the studies are, however, apparent. First, in regard to stimulation methods, the electrical method elicits pain and hyperalgesia by direct axonal stimulation, bypassing the sensory nerve endings. The heat injury leads to direct activation of nociceptors, initially by a physiological process followed by a pathophysiological inflammatory process. The electrical stimulation method is probably more suitable for examination of central components, while the heat injury method reflects both peripheral and central components of responses to noxious stimulation. Since high-intensity electrical stimulation is associated with a release of endogenous opioids, a stimulation-dependent substantial decrease in pain ratings is seen (habituation), in contrast to the heat injury where a stable increase in evoked pain responses is evident 30–45 minutes after the induction (sensitization). However, both methods seem to induce stable 2HA areas. Second, in regard to the stimulation pattern, a constant 2 Hz paradigm for 3 hours was used in the study by Koppert et al, while in the present study electrical, mechanical, and heat stimuli of a much shorter duration were used. Third, there are distinct pharmacological differences between the studies. The study by Koppert et al used 25%–50% of the buprenorphine doses used in the present study and administration was bolus-based compared to the 3-hour target-controlled infusion maintaining estimated steady-state concentration (until 1 hour after the heat injury) in the present study. These differences may explain some of the seemingly contradictory results. Interestingly, a recently published study used similar paradigm and methods to Koppert et al to investigate the additive effects of morphine and buprenorphine. The study used assessments of antihyperalgesia and analgesia as outcome parameters, but the authors did not report the ratios between these outcome parameters. Estimates of data from the accompanying graphics, however, demonstrated an absence of any differential effect between buprenorphine and fentanyl in the antihyperalgesia and analgesia profiles. The estimated ratios between antihyperalgesia and analgesia were 0.75–0.80 for both drugs.

Antihyperalgesia

In regard to the heat injury model used in the present study, four studies have been published. In a study with epidural administration of 4 mg morphine (n = 10), a reduction in 2HA areas of 25% was seen, compared to placebo. In another study with local administration of 2 mg morphine subcutaneously (n = 12) in the heat injury area, no reduction in 2HA area or signs of analgesia was seen compared to placebo. In two studies by Warncke et al (n = 12), antihyperalgesic and analgesic effects were studied following the administration of morphine (0.21 mg/kg) before and after the heat injury. Only the preinjury administration of morphine had a significant effect, with an 83% reduction in 2HA areas compared to placebo and a corresponding 41% reduction in pinprick pain threshold.

The authors are not able to explain the conflicting results between the present study and the study by Warncke et al. The sensory assessment methods, the testing paradigm, and drug-dosing scheme are almost identical in the two studies. However, an important aspect is the caliber of monofilament used in the delineation of 2HA areas. The monofilament in the study by Warncke et al had a bending force of 51 mN (5 g) compared to 890 ± 50 mN (91 ± 5 g) in the present study. Furthermore, in the study by Warncke et al, the tactile pain threshold before drug administration was 2.5 times higher than the bending force of the filament used in the assessment of 2HA, indicating stimulation well below the pain threshold. In most studies using the heat injury, the bending force of the monofilaments quantitating 2HA areas has been in the range of 20–100 g. The use of a monofilament with a very small bending force in a drug-free subject could tend to give larger hyperalgesic (ie, allodynia) areas than a rigid monofilament, which is substantiated by the fact that the median values...
during the first assessment 30 minutes after induction of the heat injury in the placebo group was 70 cm$^2$ in the Warncke et al study and 23 cm$^2$ in the present study. Correspondingly, stimulation with a light tactile stimulus during opioid exposure could, due to cognitive impairment, lead to a smaller allodynia area than stimulation with a more rigid monofilament.

**Analgesia**

The present study corroborates the analgesic effects of morphine observed in a number of studies using heat models (heat injury, heat/capsaicin, brief thermal stimulation). The present study demonstrated a consistent dose-dependent effect in all pain tests with electrical, mechanical, and thermal stimuli. The authors are not aware of any buprenorphine studies using heat models in humans.

The sedative effect of a drug may increase response latency and therefore influence reliability of quantitative sensory testing assessments in studies of analgesic efficacy. Signs of dose-dependent sedation, indicating a potential effect on vigilance and psychomotor performance, were observed for all active treatments in the present study. A drug-mediated increase of pain thresholds are either
caused by an analgesic effect, an increase in response latency, a modality specific sensory attenuating effect, or a combination of these factors. Since the baseline-corrected sensory detection thresholds (EDT and WDT) did not differ between placebo and active treatments, the dose-dependent increases in pain thresholds and tolerance (EPT, EPTo, and HPT) could mainly be attributed to specific analgesic effects rather than a prolongation of response latencies. It is noteworthy that since CDT decreased (numerical increase in threshold) significantly across active treatments, the increased CPP and CPTo, indicating analgesic efficacy, is probably in part an opioid-mediated decrease in sensitivity to cold stimuli.\(^{49,50}\)

**Equianalgesic doses**

There is controversy in the literature in regard to estimates of equianalgesic doses for buprenorphine and morphine. A number of intravenous studies have reported buprenorphine to be 25–40 times more potent than morphine.\(^{51-55}\)

Therefore, a potency ratio of 1:33 was used in the present study, ie, 0.3 mg and 0.6 mg buprenorphine corresponded to 10 mg and 20 mg of morphine, respectively. However, estimates with equianalgesic ratios from 1:60 to 1:100 have also been reported.\(^{54,55}\)

Estimates of equianalgesic doses depend in part on the pain model (experimental, clinical) and the stimulation type (electrical, mechanical, thermal) used.\(^{56}\) Although a number of testing modalities were used in the present study, it is evident by the examination of data pertaining to analgesic effects that the estimated equianalgesic ratio between buprenorphine and morphine was too high. The comparable analgesic effect for high-dose morphine and low-dose buprenorphine indicates that the ratio in the present study should have been at least 1:66 instead of 1:33. Obviously, this may influence the magnitude of the results, which are dose-dependent, but since the primary outcome is a ratio between antihyperalgesic and analgesic effects, it is more likely that the impact on the primary outcome has been limited.

**CPM**

An impaired efficiency of the CPM system seems to be an important factor in the transition from acute to chronic pain.\(^{12,57}\)

Modulation of the CPM system may therefore represent a key to preventive management of chronic pain states.\(^{58-60}\) Early studies indicated that low-dose morphine and high-dose naloxone inhibit the action of the descending pain modulation system.\(^{61,62}\) However, the only study on opioid-induced modulation of the CPM system in volunteers is a placebo-controlled study (n = 22) that used transdermal administration of fentanyl (25 µg/hour) and buprenorphine (20 µg/hour) with the CPT (3°C, 2 minutes) as the conditioning stimulus and pressure pain tolerance as the heterotopic test stimulus.\(^{12}\) Interestingly, while no analgesic effect in the 72-hour study assessed by pressure pain tolerance was demonstrated, a highly significant potentiating effect on the CPM system was seen during opioid treatment, with no significant differences between fentanyl- and buprenorphine-treated subjects. The present study, however, showed a significant dose-dependent increase in pressure pain tolerance for morphine and buprenorphine (Figure 8), a discrepancy probably explained by differences between the two studies in opioid doses and test period. The present study corroborated the finding of a potentiating effect on CPM efficiency, but only with high-dose buprenorphine (Figure 10). Further studies in volunteers are clearly needed to illuminate the diverging results from clinical studies showing either a decrease or a relative increase in the descending pain modulation system in opioid-treated patients compared to opioid-naïve patients.\(^{60,63}\)

**Pain sensitivity-dependent differences**

Pain hyposensitivity may lead to delayed or incorrect diagnoses, while pain hypersensitivity seems to be associ-
ated with an increased susceptibility to the development of chronic pain. It has been demonstrated that opioid response patterns are in part determined by opioid- and pain modality-specific analgesic response profiles. Therefore, it was considered of interest to study the relationship between pain sensitivity and analgesic response across opioids with different MOR and KOP profiles, ie, morphine and buprenorphine. In the present study, subjects were classified in regard to low or high pain sensitivity based on previous PHI. Significant differences in pain responses between subjects with low or high pain sensitivity were only found in some electrical stimulation tests at baseline and in placebo PHI. The significant differences in pain responses between subjects with low or high pain sensitivity for placebo PHI was anticipated, since this was the discriminating sensitivity test in the forerunning study. The remaining findings were most likely due to type I errors.

Methodology: limitations and advantages
Since antiemetics (hydrocortisone and ondansetron) were administered to all subjects prophylactically before drug exposure, there is a potential possibility of confounding analgesic effects. In the heat injury model, glucocorticoids have not demonstrated any analgesic or antihyperalgesic actions, although additive effects with ketorolac (a nonsteroidal antiinflammatory drug) have been proven. Ondansetron does not seem to interact with MOR agonists.

Several tests in this study examined the subjects’ tolerance level. However, all tolerance tests demonstrated ceiling effects; therefore, these tests might not be well suited for the demonstration of potential pain sensitivity differences – at least not in healthy volunteers.

In the CPM efficiency assessment, four heat stimuli (4 seconds) were delivered to the same skin site in 80 seconds. The successive decrease in pain ratings to the heat stimuli was regarded as a sign of activation of the descending pain modulation system by the conditioning cold pressor stimulus. An alternative explanation could be that the repeated heat stimuli, applied to the same site, caused peripheral habituation and a successive diminution of the pain response. It is of particular interest that some recent CPM studies have included a 5–15 minute break between the heat prestimulus (with longer duration 7–30 seconds) and the conditioning stimulus. However, temporal stimulation patterns, similar to those presented in several recent studies, were used in the present study.

A limitation of this study is the multiple comparisons made, which led to an increased probability of type I errors. Although a significance level of 0.005 was used, it cannot be ruled out that some results are a consequence of mass significance. Nevertheless, it is worth noting that most of the significant results had a P-value of 0.001 or less.

A confounding factor is that the subjects retrospectively and correctly identified the placebo treatment in 85% of the cases. This high percentage was most likely influenced by the fact that they were able to compare all five treatments before identifying the placebo and does not necessarily mean that they were aware of the treatment being placebo on the given day. The prevalence of adverse events was most likely the main cause of correct placebo identification and an active placebo could be considered in future similar studies.

The data validity was enhanced by the use of a limited number of investigators and implementation of standardized methods. Furthermore, all treatment data were corrected for baseline data. This minimizes the bias caused by day-to-day variability. All baseline data were examined for significant differences, which were only observed in three out of 80 baseline comparisons.

The study population could not be considered homogeneous in regard to gender and pain sensitivity. The data analyses, however, showed no overall or consistent differences with regard to gender or pain sensitivity. Therefore, combining the groups and investigating them as one large sample was possible.

Conclusion
In this placebo-controlled crossover study in healthy subjects, an inflammatory heat injury model with multimodal sensory testing technique was used to characterize the antihyperalgesic, analgesic, and descending pain modulation profiles of morphine and buprenorphine. The present study could not demonstrate any differences in the hyperalgesia and analgesia profiles between the opioids. High-dose buprenorphine, but not morphine, was associated with a significant increased effect of the descending inhibitory pain control system. More systematic research in the drug effects on antihyperalgesia, analgesia, and action on the descending pain modulation system is needed.

Acknowledgments
This work was supported by an unrestricted educational grant from Norpharma A/S (Hørsholm, Denmark). The authors are grateful to Sara Grünfeld, Per Rotbøll-Nielsen, and Hanne M. Hansen for their valuable contribution in surveillance of the study volunteers. The authors appreciate the scientific discussions with Dorthe TvinneMose. The authors highly
appreciate the opportunity to use the facilities at the Phase One Trial Unit (ZELO) at Bispebjerg Hospital (Copenhagen, Denmark) and thank Torben Balchen and Jesper Sonne for their help and hospitality. The help of Philip Hojrizi with the study drugs is highly appreciated.

Disclosure

The authors report no conflicts of interest in this work.

References


